Expanding the Molecular Data of DICER1 ‐Related Tumor Predisposition: Novel Germline Variants in an Argentine Pediatric Cohort
Authors:
- Sofía TroboSTSofía Trobo
- Natalia Pérez GarridoNGNatalia Pérez Garrido
- Pablo RamírezPRPablo Ramírez
- Fiorella TesanFTFiorella Tesan
- Elisa VaianiEVElisa Vaiani
- Noelia DujovneNDNoelia Dujovne
- Natalia GazekNGNatalia Gazek
- Jessica Lopez MartíJMJessica Lopez Martí
- Mariana LaviaMLMariana Lavia
- Guido FelizziaGFGuido Felizzia
- Victoria PringlesVPVictoria Pringles
- Melisa AgotegarayMAMelisa Agotegaray
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 3621830
Abstract
Background/Objective: DICER1 ‐related tumor predisposition is a rare hereditary tumor predisposition disorder characterized by autosomal dominant inheritance, reduced penetrance, and variable expressivity. This study is aimed at describing the clinical and molecular spectrum of DICER1 ‐related tumor predisposition in an Argentine pediatric cohort. Design and Methods: Seventeen unrelated patients with DICER1 ‐related tumor predisposition and 54 relatives were evaluated at “Prof. Dr. J. P. Garrahan” Pediatric Hospital (Buenos Aires, Argentina) between 2014 and 2024. Germline and somatic DICER1 variants were analyzed using Sanger or next‐generation sequencing. Functional assays were performed for selected intronic variants. Three samples of poorly differentiated thyroid carcinoma were also included. Results: Sixteen distinct germline variants were identified in the 17 index cases, including 12 novel alterations (75%). One quarter of the variants were de novo. Thyroid involvement, particularly multinodular goiter and papillary thyroid carcinoma, was the most common presentation and frequently coexisted with ovarian Sertoli–Leydig cell tumors or embryonal rhabdomyosarcoma. Two novel intronic variants were confirmed to affect splicing by RT‐PCR. Somatic “hotspot” mutations in exons 24–25 (RNase IIIb domain) were detected in most tumors, consistent with the two‐hit model. The identification of asymptomatic carriers enabled early surveillance and preventive interventions. Conclusions: This study expands the molecular spectrum of germline DICER1 variants, reinforces the predominance of thyroid involvement, and highlights the value of molecular testing for diagnosis, genetic counseling, and early intervention. Ethical considerations regarding surveillance and management of asymptomatic carriers remain an important area in need of future guidance.Keywords
This publication has 40 references indexed in Scilit:
- PRAME protein expression in DICER1‐related tumoursThe Journal of Pathology: Clinical Research, 2022
- A child with neuroblastoma and metachronous anaplastic sarcoma of the kidney: Underlying DICER1 syndrome?Pediatric Blood & Cancer, 2020
- Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypesHuman Mutation, 2019
- Multiple DICER1‐related tumors in a child with a large interstitial 14q32 deletionGenes, Chromosomes and Cancer, 2018
- DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care centerPediatric Blood & Cancer, 2017
- A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation?Pediatric Blood & Cancer, 2017
- Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutationsActa Neuropathologica, 2014
- DICER1mutations in an adolescent with cervical embryonal rhabdomyosarcoma (cERMS)Pediatric Blood & Cancer, 2013
- DICER1 Mutations in embryonal rhabdomyosarcomas from children with and without familial PPB‐tumor predisposition syndromePediatric Blood & Cancer, 2011
- DICER1 Mutations in Familial Multinodular Goiter With and Without Ovarian Sertoli-Leydig Cell TumorsJAMA, 2011